Literature DB >> 3005437

Polypeptide-specific antibody response to human cytomegalovirus after infection in bone marrow transplant recipients.

J A Zaia, S J Forman, Y P Ting, E Vanderwal-Urbina, K G Blume.   

Abstract

Human cytomegalovirus (HCMV) infection continues to be the most important infection occurring after allogeneic bone marrow transplantation (BMT). Although T cell-specific antiviral immunity appears to be necessary for control of the infection, the humoral immune reaction also contributes to a complete immune response. In this paper we report our findings concerning the antibody response to the individual polypeptides of HCMV in patients who had undergone BMT and subsequently had displayed evidence of HCMV infection. Sera obtained from the subjects during and after HCMV viremia were studied by using both a radioimmunoprecipitation assay and an immunoblot assay, and the results were compared with the pattern of antibody response in normal individuals. The results show that the BMT patient can make antibodies to individual proteins of HCMV in a pattern similar to that displayed by persons with natural infection. The polypeptide-specific antibody response present most frequently was directed to proteins of 64 kDa, 50 kDa, and 36 kDa. Some BMT recipients also produced antibody to a wide range of HCMV proteins: 183 kDa, 155 kDa, 130 kDa, 110 kDa, 92 kDa, 86 kDa, 74 kDa, 71 kDa, 69 kDa, 39-44 kDa, 33 kDa, and 29 kDa.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3005437     DOI: 10.1093/infdis/153.4.780

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus.

Authors:  B Wagner; B Kropff; H Kalbacher; W Britt; V A Sundqvist; L Ostberg; M Mach
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

2.  Human cytomegalovirus pp65 lower matrix protein: a humoral immunogen for systemic lupus erythematosus patients and autoantibody accelerator for NZB/W F1 mice.

Authors:  M Chang; M-R Pan; D-Y Chen; J-L Lan
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

Review 3.  Molecular biology and immunology of cytomegalovirus.

Authors:  P D Griffiths; J E Grundy
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

4.  Comparative sequence analysis of human cytomegalovirus strains.

Authors:  R Lehner; T Stamminger; M Mach
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

5.  Identification, analysis, and evolutionary relationships of the putative murine cytomegalovirus homologs of the human cytomegalovirus UL82 (pp71) and UL83 (pp65) matrix phosphoproteins.

Authors:  L D Cranmer; C L Clark; C S Morello; H E Farrell; W D Rawlinson; D H Spector
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Human antibody reactivity against the lower matrix protein (pp65) produced by cytomegalovirus.

Authors:  M Ohlin; B Plachter; V A Sundqvist; P G Steenbakkers; J M Middeldorp; C A Borrebaeck
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

7.  The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific.

Authors:  M Urban; W Britt; M Mach
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

Review 8.  Viral infections in severely immunocompromised cancer patients.

Authors:  S M Devine; J R Wingard
Journal:  Support Care Cancer       Date:  1994-11       Impact factor: 3.603

Review 9.  Humoral immune response to human cytomegalovirus infection: diagnostic potential of immunoglobulin class and IgG subclass antibody response to human cytomegalovirus early and late antigens.

Authors:  B Weber; W Braun; J Cinatl; H W Doerr
Journal:  Clin Investig       Date:  1993-04

10.  Identification and procaryotic expression of the gene coding for the highly immunogenic 28-kilodalton structural phosphoprotein (pp28) of human cytomegalovirus.

Authors:  H Meyer; A T Bankier; M P Landini; C M Brown; B G Barrell; B Rüger; M Mach
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.